Year All202620252024202320222021 March 17, 2026 ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting March 5, 2026 ArriVent BioPharma Reports Full Year 2025 Financial Results December 22, 2025 ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer November 10, 2025 ArriVent BioPharma Reports Third Quarter 2025 Financial Results September 22, 2025 ArriVent Appoints Brent S. Rice as Chief Commercial Officer September 9, 2025 Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer August 11, 2025 ArriVent BioPharma Reports Second Quarter 2025 Financial Results July 21, 2025 ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026 July 1, 2025 ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants July 1, 2025 ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants
March 17, 2026 ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting
December 22, 2025 ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer
September 9, 2025 Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer
July 21, 2025 ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026
July 1, 2025 ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
July 1, 2025 ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants
